Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$0.63 USD
+0.01 (1.35%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.63 0.00 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Bolt Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -69.20 | -88.10 | -98.59 | -60.73 | -30.49 |
Depreciation/Amortization & Depletion | -2.64 | 1.85 | 4.17 | 0.65 | 0.34 |
Net Change from Assets/Liabilities | -3.41 | 2.77 | 6.68 | 2.88 | 2.12 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.72 | 6.98 | 30.68 | 9.89 | 1.69 |
Net Cash From Operating Activities | -69.53 | -76.50 | -57.07 | -47.31 | -26.34 |
Property & Equipment | -0.21 | -1.95 | -2.34 | -3.26 | -0.51 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 71.24 | 59.82 | -229.86 | -17.33 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 71.04 | 57.86 | -232.20 | -20.59 | -0.51 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.25 | 0.50 | 66.79 | 0.29 | 0.07 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 244.32 | 39.30 | 48.60 |
Net Cash from Financing Activities | 0.25 | 0.50 | 311.11 | 39.60 | 48.63 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1.77 | -18.14 | 21.84 | -28.30 | 21.78 |
Cash at Beginning of Period | 10.81 | 28.95 | 7.11 | 35.41 | 13.63 |
Cash at End of Period | 12.58 | 10.81 | 28.95 | 7.11 | 35.41 |
Diluted Net EPS | -1.83 | -2.36 | -2.97 | -28.89 | NA |
Fiscal Year End for Bolt Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -32.01 | -10.81 | -69.20 | -51.29 | -35.04 |
Depreciation/Amortization & Depletion | -0.91 | -0.58 | -2.64 | -1.91 | -1.04 |
Net Change from Assets/Liabilities | -2.63 | -3.54 | -3.41 | -4.60 | -5.43 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.65 | -1.82 | 5.72 | 2.55 | 2.99 |
Net Cash From Operating Activities | -32.89 | -16.75 | -69.53 | -55.26 | -38.51 |
Property & Equipment | 0.00 | 0.00 | -0.21 | -0.20 | -0.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 28.21 | 10.20 | 71.24 | 55.43 | 42.61 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 28.21 | 10.20 | 71.04 | 55.23 | 42.57 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.08 | 0.00 | 0.25 | 0.15 | 0.15 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.08 | 0.00 | 0.25 | 0.15 | 0.15 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -4.61 | -6.55 | 1.77 | 0.12 | 4.21 |
Cash at Beginning of Period | 12.58 | 12.58 | 10.81 | 10.81 | 10.81 |
Cash at End of Period | 7.97 | 6.03 | 12.58 | 10.93 | 15.02 |
Diluted Net EPS | -0.56 | -0.28 | -0.47 | -0.43 | -0.48 |